Name

Smartlens

Legal name

Smartlens, Inc.

Website

https://smartlens.health

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices / Glaucoma Monitoring

NAICS

Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)

akta.pro secondary industries

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)

Keywords

• Glaucoma monitoring devices
• Intraocular pressure sensors
• Microfluidic contact lens
• Ophthalmic diagnostics
• Anterior segment imaging

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. miLens Contact Lens Hardware: Sale of the miLens electronics-free contact lens device for continuous IOP monitoring. The non-invasive device is designed for glaucoma patients requiring diurnal pressure monitoring.
2. miLens IQ+ Analytics Subscription: AI/ML-powered analytics platform that integrates with miLens and imaging data to provide real-time risk stratification and data-driven analysis for treatment decisions. Likely subscription-based model for continuous access to analytics.
3. THERx IQ Medication Delivery Platform: Automated micro-dose medication delivery device with programmable treatment timing. Revenue from device sales and potentially refills/replacements of medication cartridges.
4. Anterior Segment Platform Services: AI-powered remote examination platform providing telemedicine capabilities for anterior segment disease assessment. Revenue from platform access/subscription for eyecare practitioners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Smartlens fundamentally develops and sells the miLens electronics-free microfluidic contact lens system for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients, integrated with the miLens IQ+ AI/ML analytics platform and Slit IQ smartphone imaging. The portfolio is expanding into the Smartlens Anterior Segment Platform for AI-powered remote examination of multiple anterior segment conditions and the THERx IQ automated micro-dose medication delivery wearable. Customers are ophthalmologists, eyecare practitioners, and eyecare institutions seeking continuous monitoring, AI-driven risk stratification, and treatment optimization tools.

Product overview

Smartlens offers an integrated ophthalmic monitoring and treatment platform comprising four core products: miLens (electronics-free contact lens for continuous 24/7 IOP monitoring), miLens IQ+ (AI/ML-powered analytics platform for risk stratification), Smartlens Anterior Segment Platform (AI-powered remote examination system), and THERx IQ (automated micro-dose medication delivery device). The platform combines microfluidic technology with AI-enhanced diagnostics to enable continuous monitoring, diagnosis, and treatment optimization for anterior segment diseases, moving from episodic office visits to continuous, data-driven care management.

Differentiator

Problem solved

Functional benefit

Brands

• miLens: World's smallest wearable microfluidic device for continuous intraocular pressure (IOP) monitoring in glaucoma patients. Electronics-free contact lens designed for diurnal monitoring that works with smartphone-based imaging system.
• miLens IQ+
• THERx IQ
• Slit IQ
• Smartlens Anterior Segment Platform

Products and services

• miLens The world's smallest wearable microfluidic device and first electronics-free contact lens for continuous 24/7 diurnal intraocular pressure (IOP) monitoring in glaucoma patients. Designed for remote use with a smartphone-based imaging system, miLens captures critical diurnal pressure variations missed by quarterly or annual office-based measurements and enables early detection of dangerous IOP spikes. Built for ophthalmologists, glaucoma specialists, optometrists, and eyecare institutions managing glaucoma patients.
• miLens IQ+ AI/ML-powered analytics platform that unlocks insights from first-of-its-kind diurnal IOP monitoring and comprehensive imaging data. Integrates pressure patterns from miLens with standardized anterior segment imaging to provide real-time risk stratification, predictive capabilities, and data-driven analysis to inform treatment decisions. Eliminates subjective variability through standardized, quantifiable measurements.
• Smartlens Anterior Segment Platform AI-powered remote examination platform providing comprehensive monitoring of all anterior segment conditions including Dry Eye, Cataracts, Conjunctivitis, Blepharitis, Episcleritis, Scleritis, Pterygium, Anterior Uveitis, and Trauma. Facilitates telemedicine capabilities and standardizes disease assessment through AI-powered grading and enhanced monitoring, expanding specialist access across geographic barriers.
• THERx IQ Novel wearable device providing automated personalized micro-dose medication delivery for chronic eye diseases, with initial focus on glaucoma treatment. Addresses poor medication adherence and imprecise dosing through programmable micro-dosing technology that optimizes treatment timing based on each patient's pressure patterns, enhancing therapeutic efficacy while minimizing side effects common with traditional eye drops.
• Slit IQ Smartphone-based imaging platform that integrates with miLens for capturing and analyzing eye pressure data and anterior segment imaging. AI-powered to work seamlessly with the miLens contact lens system for comprehensive remote ophthalmic examination.

Quantifiable outcome

• 96.2% practitioner adoption intent based on clinical data
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• CATS Tonometer (Cornea Health): Developer of a corneal applanation tonometer designed for continuous, in-eye IOP monitoring using a contact lens form factor. CATS represents an emerging player with technical overlap to Smartlens's contact-lens-based IOP monitoring approach.
• InWith Corp: Emerging developer of smart contact lens platforms with embedded electronics for vision and health applications. InWith represents an emerging competitive threat in the smart contact lens category, though with a different technical approach than Smartlens's electronics-free microfluidics.

Broad incumbents

• Reichert Technologies (AMETEK): Long-established manufacturer of Goldmann and non-contact tonometers used as the clinical gold standard for IOP measurement. Reichert represents the entrenched incumbent workflow Smartlens must displace or augment.
• Haag-Streit (Metall Zug Group): Swiss manufacturer of ophthalmic diagnostic equipment including slit lamps and tonometers. Haag-Streit is an incumbent in the eyecare diagnostics workflow where Smartlens's Slit IQ smartphone imaging platform competes.
• Alcon: Global ophthalmic medtech leader with broad glaucoma, cataract, and contact lens portfolios. Alcon is a strategic competitor and potential acquirer with the commercial scale Smartlens would need to reach the full eyecare practitioner market.
• Glaukos Corporation: Public medtech company specializing in MIGS devices and sustained pharmaceutical delivery for glaucoma. Glaukos is a comparable glaucoma-focused commercial medtech and represents a potential strategic acquirer or benchmark for Smartlens's commercial trajectory.
• Bausch + Lomb (Bausch Health): Diversified ophthalmic company with glaucoma pharmaceutical, surgical, and contact lens offerings. Bausch + Lomb operates broadly across the glaucoma care continuum that Smartlens is targeting with its integrated platform.

Direct peers

• Sensimed: Swiss developer of the Triggerfish, a CE-marked smart contact lens for 24-hour continuous IOP monitoring in glaucoma. Sensimed is the most direct competitor in continuous IOP-monitoring contact lenses, addressing the same clinical use case as Smartlens's miLens.
• Icare (Icare Finland Oy / Revenio Group): Manufacturer of rebound tonometers (Icare IC100, Icare HOME) used for in-office and self-measured IOP. Icare is a direct competitor offering an alternative point-of-care and home-based IOP measurement paradigm for glaucoma management.

Regional players

• Lupin Pharmaceuticals: India-based ophthalmic pharmaceutical company expanding into glaucoma therapeutics and diagnostics. Lupin represents a regional player with overlapping interest in the anterior segment and glaucoma management market that Smartlens addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/smartlens-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Smartlens